Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 211 AL 225

Recruitment of subjects into clinical trials for Alzheimer disease

Knebl JA, Patki D.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S43-9.

Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?

Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B.

Int J Neurosci. 2010 Dec;120(12):746-51. doi: 10.3109/00207454.2010.520381. Epub 2010 Oct 13.

Novel drug targets based on metallobiology of Alzheimer's disease

Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT.

Expert Opin Ther Targets. 2010 Nov;14(11):1177-97. doi: 10.1517/14728222.2010.525352.

Wnt signalling is a relevant pathway contributing to amyloid beta- peptide-mediated neuropathology in Alzheimer's disease

da Cruz e Silva OA, Henriques AG, Domingues SC, da Cruz e Silva EF.

CNS Neurol Disord Drug Targets. 2010 Dec;9(6):720-6. doi: 10.2174/187152710793237458.

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease]

Wang XH, Yang W, Qi JS.

Sheng Li Xue Bao. 2010 Oct 25;62(5):398-406.

[Molecular targeted therapy in Alzheimer disease]

Morohashi Y, Tomita T, Iwatsubo T.

Nihon Rinsho. 2010 Oct;68(10):1906-10.

Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

Guo S, Hernandez L, Wasiak R, Gaudig M.

J Med Econ. 2010;13(4):641-54. doi: 10.3111/13696998.2010.528101. Epub 2010 Oct 19.

[Alteration of calcium signaling as one of the mechanisms of Alzheimer's disease and diabetic polyneuropathy]

Kostiuk OP, Korol' TIu, Korol' SV, Romanenko SV, Pinchenko VO, Kostiuk PH.

Fiziol Zh (1994). 2010;56(4):130-8.

Is dementia preventable? Focus on Alzheimer's disease

Barak Y, Aizenberg D.

Expert Rev Neurother. 2010 Nov;10(11):1689-98. doi: 10.1586/ern.10.159.

[Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)]

Agüera-Ortiz LF; Grupo de Investigadores del Estudio MEMORY.

Rev Neurol. 2010 Nov 1;51(9):525-34.

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial

Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS.

JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510.

Inflammation and Alzheimer's disease

Lee YJ, Han SB, Nam SY, Oh KW, Hong JT.

Arch Pharm Res. 2010 Oct;33(10):1539-56. doi: 10.1007/s12272-010-1006-7. Epub 2010 Oct 30.

Potential therapeutic agents against Alzheimer's disease from natural sources

Park SY.

Arch Pharm Res. 2010 Oct;33(10):1589-609. doi: 10.1007/s12272-010-1010-y. Epub 2010 Oct 30.

A meta-analysis of mood stabilizers for Alzheimer's disease

Xiao H, Su Y, Cao X, Sun S, Liang Z.

J Huazhong Univ Sci Technolog Med Sci. 2010 Oct;30(5):652-8. doi: 10.1007/s11596-010-0559-5. Epub 2010 Nov 10.

Detection of Aβ plaques by a novel specific MRI probe precursor CR-BSA-(Gd-DTPA)n in APP/PS1 transgenic mice

Li S, He H, Cui W, Gu B, Li J, Qi Z, Zhou G, Liang CM, Feng XY.

Anat Rec (Hoboken). 2010 Dec;293(12):2136-43. doi: 10.1002/ar.21209.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias